Oil Giant Shell Marks Its First African Power Deal, With Acquisition Of Nigerian Solar Energy Provider – Shell (NYSE:SHEL)
[ad_1] Shell plc SHEL has made its first power sector acquisition in Africa by purchasing a renewable energy provider, Daystar Power. Daystar operates in Nigeria, Ghana, and three other countries across…
TCR2 Therapeutics Shares Jump After Additional Reponses in Ovarian Cancer, Mesothelioma – TCR2 Therapeutics (NASDAQ:TCRR)
[ad_1] TCR2 Therapeutics Inc TCRR has announced topline results from the Phase 1 portion of the gavo-cel Phase 1/2 trial for mesothelin-expressing solid tumors. Gavo-cel demonstrated a disease control rate (DCR)…
Thermo Fisher’s Oncomine Dx Test Is First FDA Approved NGS-Based Companion Diagnostic To Detect Thyroid Cancers – Thermo Fisher Scientific (NYSE:TMO)
[ad_1] by Vandana Singh, Benzinga Editor September 28, 2022 8:11 AM | 1 min read The FDA approved Thermo Fisher Scientific Inc’s TMO Oncomine Dx Target Test as a companion diagnostic (CDx)…
European Drug Makers Say Higher Energy Costs Eating Margins: Report – Teva Pharmaceutical Indus (NYSE:TEVA)
[ad_1] Europe’s drug makers have warned about stopping manufacturing some cheap generic medicines amid surging electricity costs. The generic drug industry lobby group, Medicines for Europe, representing Teva Pharmaceutical…
X4 Pharma Highlights New Data Supporting Mavorixafor’s Broad Potential In Chronic Neutropenia – X4 Pharmaceuticals (NASDAQ:XFOR)
[ad_1] X4 Pharmaceuticals Inc XFOR announced new data from its Phase 1b trial evaluating the ability of its lead clinical candidate, mavorixafor, to increase the absolute neutrophil count (ANC) in chronic neutropenia…
Enalare Secures BARDA Award Of $50M For ENA-001 In Drug Overdose – Eagle Pharmaceuticals (NASDAQ:EGRX)
[ad_1] Eagle Pharmaceuticals Inc EGRX announced that Enalare Therapeutics Inc secured a contract for up to $50.3 million from the Biomedical Advanced Research and Development Authority (BARDA). In partnership with BARDA, ENA-001 is…
Corvus Pharma’s Partner Secures China Approval For Early-Stage Mupadolimab Trial For Lung, Head & Neck Cancer – Corvus Pharmaceuticals (NASDAQ:CRVS)
[ad_1] The China National Medical Products Administration signed off Corvus Pharmaceuticals Inc’s CRVS IND application to initiate a Phase 1/1b trial of mupadolimab (formerly CPI-006). The study will be conducted by Angel…
Japan Approves AstraZeneca’s Two Treatments For Asthma, Rare Form Of Cancer – AstraZeneca (NASDAQ:AZN), AstraZeneca (OTC:AZNCF)
[ad_1] Japan’s health agency has approved AstraZeneca Plc’s AZN Koselugo (selumetinib) for pediatric patients with plexiform neurofibromas (PNs) in neurofibromatosis type 1 (NF1) with clinical symptoms and which cannot be entirely removed…
Biogen Settles For $900M In Bribe Case For Prescribing Multiple Sclerosis Drugs – Biogen (NASDAQ:BIIB)
[ad_1] Biogen Inc BIIB has reached a $900 million settlement with a whistleblower who accused the firm of paying doctors bribes to encourage them to prescribe its multiple sclerosis drugs. The…
US Agency EEOC Files Lawsuit Against Eli Lilly Over Nationwide Age Discrimination – Eli Lilly (NYSE:LLY)
[ad_1] The U.S. Equal Employment Opportunity Commission (EEOC) accused Eli Lilly And Co LLY of illegally refusing to hire older workers for sales representative jobs because of their age. According to…
Lipocine To Focus On Central Nervous System Conditions; Explores Partnerships For Non-Core Assets – Lipocine (NASDAQ:LPCN)
[ad_1] Lipocine Inc LPCN announced its plans to focus on treating Central Nervous System (CNS) disorders. The company’s priority is to advance its endogenous neuroactive steroids (NAS) pipeline. The CNS development…
Gain Therapeutics Touts Additional Encouraging Preclinical Data For Lead Parkinson’s Program – Gain Therapeutics (NASDAQ:GANX)
[ad_1] Gain Therapeutics Inc GANX announced the presentation of new preclinical data evaluating one of its lead Structurally Targeted Allosteric Regulator (STAR) compounds, GT-02287, for Parkinson’s Disease. The study was conducted…
SIGA Announces $16M Procurement Orders For Its Monkeypox Treatment – SIGA Technologies (NASDAQ:SIGA)
[ad_1] SIGA Technologies Inc SIGA received approximately $16 million in international procurement orders for oral TPOXX (tecovirimat) in August and early September. The orders include an approximate $10 million order by…
LAVA Therapeutics Skyrockets After Cancer Agreement With Seagen – Seagen (NASDAQ:SGEN)
[ad_1] Seagen Inc SGEN has announced an exclusive license agreement to develop, manufacture and commercialize LAVA Therapeutics N.V.’s LVTX LAVA-1223. LAVA-1223 is a preclinical asset that utilizes LAVA’s proprietary Gammabody technology to target…
Switzerland To Dispose 10M Expired COVID-19 Vaccine Doses From Moderna – Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX)
[ad_1] Switzerland would have to discard 10.3 million doses of Moderna Inc’s MRNA COVID-19 vaccine, the health ministry said Saturday. The ministry said it had no choice but to eliminate the shots…
Despite Regulatory Setback, Spectrum Still “Unique Investment Opportunity,” Says Analyst – Spectrum Pharmaceuticals (NASDAQ:SPPI)
[ad_1] Yesterday, the FDA’s Oncologic Drugs Advisory Committee (ODAC) panel voted against Spectrum Pharmaceuticals Inc’s SPPI poziotinib’s (pozi) risk/benefit ratio and concluded that pozi’s benefits do not outweigh the risks for the…
Why Avenue Therapeutics (ATXI) Shares Are Falling Today – Avenue Therapeutics (NASDAQ:ATXI)
[ad_1] Avenue Therapeutics Inc ATXI received the official meeting minutes from the FDA regarding a meeting conducted for IV Tramadol in combination with other opioid analgesics to manage moderate-to-moderately severe pain. …
FDA’s Adcomm Gives Thumbs Down To Spectrum Pharmaceuticals’ Lung Cancer Candidate – Spectrum Pharmaceuticals (NASDAQ:SPPI)
[ad_1] Following the release of scathing briefing documents, FDA’s Oncologic Drugs Advisory Committee voted 9-4 against Spectrum Pharmaceuticals Inc’s SPPI poziotinib benefit-risk profile. FDA presenters said significant issues with the poziotinib…
Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings – Citius Pharmaceuticals (NASDAQ:CTXR)
[ad_1] Citius Pharmaceuticals Inc CTXR collaborated with the University of Pittsburgh for I/ONTAK (denileukin diftitox or E7777) in combination with Merck & Company, Inc. MRK Keytruda (pembrolizumab) for recurrent or metastatic solid tumors. …
Luna Innovations Shares Pop After New Contract With Medtech Giant Intuitive Surgical – Intuitive Surgical (NASDAQ:ISRG), Luna Innovations (NASDAQ:LUNA)
[ad_1] Luna Innovations Inc LUNA announced a new $14.2 million contract with its long-standing partner Intuitive Surgical Inc ISRG. This new agreement provides for the supply of critical photonic subsystems manufactured by Luna…
Top Financial Media Stories Thursday, September 22: Facebook Sued For Bypassing Apple Privacy Rules, Walmart Slows Hiring Plans Ahead Of Holiday Season, China Blames US For Northwestern Polytechnical University Hack And More.. – Apple (NASDAQ:AAPL), Amazon.com (NASDAQ:AMZN)
[ad_1] Reuters CATL’s 3rd Largest Customer After Tesla, Nio Cuts Reliance On Battery Giant In Bid For Diversification XPeng Inc XPEV has diversified its battery suppliers and does not…
Inventiva Inks Licensing Pact With China-Based Sino Biopharm For NASH Candidate In Greater China – Inventiva (NASDAQ:IVA)
[ad_1] Inventiva IVA and Chia Tai-Tianqing Pharmaceutical Group Co Ltd, a Sino Biopharm subsidiary, have entered into a licensing and collaboration agreement to develop and commercialize lanifibranor for non-alcoholic steatohepatitis (NASH) and potentially other metabolic…
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma – AstraZeneca (NASDAQ:AZN), AstraZeneca (OTC:AZNCF), Daiichi Sankyo Co (OTC:DSNKY), Daiichi Sankyo Co (OTC:DSKYF)
[ad_1] On Tuesday, the FDA released briefing documents related to Spectrum Pharmaceutical Inc’s SPPI application for poziotinib for treating patients with previously treated locally advanced or metastatic NSCLC. HC Wainwright says that though…
Some Medtronic’s Insulin Pumps Are Associated With Cybersecurity Risk, FDA Says – Medtronic (NYSE:MDT)
[ad_1] The FDA warned that certain types of Medtronic Inc’s MDT MiniMed 600 Series insulin pump system were vulnerable to cyberattacks. Hackers could potentially hamper insulin delivery by accessing the device. …
Pacira Touts Positive Data From EXPAREL Study In Toe Correction Surgery – Pacira BioSciences (NASDAQ:PCRX)
[ad_1] Pacira BioSciences Inc PCRX announced topline results from its Phase 3 study of EXPAREL as a single-dose sciatic nerve block in the popliteal fossa for postsurgical regional analgesia in patients undergoing…